Medibio Named Finalist for Prestigious Optus My Business Award
The awards are the longest-standing business awards program in Australia, identifying and acknowledging the achievements of Australia’s best business operators
MINNEAPOLIS, Minn. and SYDNEY, Australia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF) has been shortlisted as a finalist in the Health Services Business of the Year category at the 2018 Optus My Business Awards, the premier event of the year for small and medium-sized enterprises.
is a mental health technology company that is pioneering the use of digital biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. As a world leader in objective measurement for mental health, the company’s technology detects dysfunction within the areas of the body regulated by the autonomic nervous system (ANS).
The Optus My Business Awards, which covers 28 categories, acknowledges best practice within a particular industry sector, as well as individual business leaders, excellence in customer service and achievements in innovation, corporate social responsibility and workplace culture. Winners from company-related categories will be shortlisted for the highly coveted Business of the Year Award.
“Small and medium-sized businesses are undeniably the backbone of our nation’s economy, as well as the heart of our local communities,” said Adam Zuchetti, editor of My Business. “It is wonderful to be able to recognise them on their achievements in service delivery, product innovation, workplace excellence and commitment to sustainability.”
He added: “Every year, both the number and the quality of submissions we receive for the Optus My Business Awards gets better, making it an ever-more impressive feat for those stand-out businesses who are named finalists. Our judges really have their work cut out for them in trying to select this year’s winners!”
“Medibio’s recognition for innovation in the health services community reinforces the need for our technology’s objective measures to diagnose and monitor mental health for our friends and loved ones,” said Brian Mower, Interim CEO for Medibio. “We are thrilled by this nomination for an Optus My Business Award.”
The winners will be announced at a black tie awards dinner on Friday, 9 November at The Star, Sydney.
More information on Medibio can be found at .
About Medibio Limited
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on and
| Further Information: Website: | |
| Medibio Enquiries: Josh Purdy Senior Public Relations Manager Medibio Limited T: | Australian Media Enquiries: Peter Taylor NWR Communications T: +61 (0) 412 036 231 |
